334 related articles for article (PubMed ID: 19297519)
1. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.
McDonald MG; Rieder MJ; Nakano M; Hsia CK; Rettie AE
Mol Pharmacol; 2009 Jun; 75(6):1337-46. PubMed ID: 19297519
[TBL] [Abstract][Full Text] [Related]
2. Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy.
Hirai K; Yamada Y; Hayashi H; Tanaka M; Izumiya K; Suzuki M; Yoshizawa M; Moriwaki H; Akimoto T; Tsuji D; Inoue K; Itoh K
Thromb Res; 2015 May; 135(5):861-6. PubMed ID: 25747538
[TBL] [Abstract][Full Text] [Related]
3. CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects.
Nakamura K; Obayashi K; Araki T; Aomori T; Fujita Y; Okada Y; Kurabayashi M; Hasegawa A; Ohmori S; Nakamura T; Yamamoto K
J Clin Pharm Ther; 2012 Aug; 37(4):481-5. PubMed ID: 22172097
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP4F2 polymorphisms and plasma vitamin K levels on warfarin sensitivity in Japanese pediatric patients.
Hirai K; Hayashi H; Ono Y; Izumiya K; Tanaka M; Suzuki T; Sakamoto T; Itoh K
Drug Metab Pharmacokinet; 2013; 28(2):132-7. PubMed ID: 22892446
[TBL] [Abstract][Full Text] [Related]
5. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
[TBL] [Abstract][Full Text] [Related]
6. Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.
Ma C; Zhang Y; Xu Q; Yang J; Zhang Y; Gao L; Xu B; Wang H; Li Y; Lu C; Yin T
Int J Hematol; 2012 Dec; 96(6):719-28. PubMed ID: 23104259
[TBL] [Abstract][Full Text] [Related]
7. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.
Scott SA; Khasawneh R; Peter I; Kornreich R; Desnick RJ
Pharmacogenomics; 2010 Jun; 11(6):781-91. PubMed ID: 20504253
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients.
Zhuang W; Wen W; Xuan B; Chen Y; Cao Y; Sun Z; Ma J
Blood Coagul Fibrinolysis; 2015 Mar; 26(2):167-74. PubMed ID: 25304014
[TBL] [Abstract][Full Text] [Related]
9. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
[TBL] [Abstract][Full Text] [Related]
10. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.
Biss TT; Avery PJ; Brandão LR; Chalmers EA; Williams MD; Grainger JD; Leathart JB; Hanley JP; Daly AK; Kamali F
Blood; 2012 Jan; 119(3):868-73. PubMed ID: 22010099
[TBL] [Abstract][Full Text] [Related]
11. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.
Borgiani P; Ciccacci C; Forte V; Sirianni E; Novelli L; Bramanti P; Novelli G
Pharmacogenomics; 2009 Feb; 10(2):261-6. PubMed ID: 19207028
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients.
Singh O; Sandanaraj E; Subramanian K; Lee LH; Chowbay B
Drug Metab Pharmacokinet; 2011; 26(2):130-6. PubMed ID: 21084764
[TBL] [Abstract][Full Text] [Related]
13. The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients.
Wattanachai N; Kaewmoongkun S; Pussadhamma B; Makarawate P; Wongvipaporn C; Kiatchoosakun S; Vannaprasaht S; Tassaneeyakul W
Eur J Clin Pharmacol; 2017 Aug; 73(8):973-980. PubMed ID: 28550460
[TBL] [Abstract][Full Text] [Related]
14. Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.
Wypasek E; Branicka A; Awsiuk M; Sadowski J; Undas A
Thromb Res; 2014 Sep; 134(3):604-9. PubMed ID: 25042728
[TBL] [Abstract][Full Text] [Related]
15. Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction.
Kringen MK; Haug KB; Grimholt RM; Stormo C; Narum S; Opdal MS; Fosen JT; Piehler AP; Johansen PW; Seljeflot I; Berg JP; Brørs O
J Biomed Biotechnol; 2011; 2011():739751. PubMed ID: 21127708
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy.
Pérez-Andreu V; Roldán V; Antón AI; García-Barberá N; Corral J; Vicente V; González-Conejero R
Blood; 2009 May; 113(20):4977-9. PubMed ID: 19270263
[TBL] [Abstract][Full Text] [Related]
17. Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis.
Liang R; Wang C; Zhao H; Huang J; Hu D; Sun Y
Thromb Res; 2012 Jul; 130(1):38-44. PubMed ID: 22192158
[TBL] [Abstract][Full Text] [Related]
18. The frequency of CYP2C9, VKORC1, and CYP4F2 polymorphisms in Russian patients with high thrombotic risk.
Ivashchenko D; Rusin I; Sychev D; Grachev A
Medicina (Kaunas); 2013; 49(12):517-21. PubMed ID: 24858991
[TBL] [Abstract][Full Text] [Related]
19. Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation.
Li J; Yang W; Xie Z; Yu K; Chen Y; Cui K
BMC Cardiovasc Disord; 2018 May; 18(1):96. PubMed ID: 29776386
[TBL] [Abstract][Full Text] [Related]
20. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
An SH; Chang BC; Lee KE; Gwak HS
Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
